Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 23, 2026, 1:29 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1201–1224 of 2,374 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Visual Function Clear all
Terminated Not applicable Interventional Results available

Efficacy of the Nanodropper Device on Intraocular Pressure in Patients With Glaucoma

NCT05273385
View directory record Official record
Conditions
Glaucoma, Ocular Hypertension, Open Angle Glaucoma
Interventions
Nanodropper
Device
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Mar 5, 2026 · Synced Oct 23, 2026, 1:29 AM EDT
Active, not recruiting Phase 2 Interventional Results available

Tepotinib Phase II in NSCLC Harboring MET Alterations (VISION)

NCT02864992
View directory record Official record
Conditions
Advanced (Stage IIIB/IV) Non-small Cell Lung Cancer (NSCLC) With MET Exon 14 (METex14) Skipping Alterations or MET Amplification, Lung Adenocarcinoma Stage IIIB/IV
Interventions
Tepotinib
Drug
Lead sponsor
EMD Serono Research & Development Institute, Inc.
Industry
Eligibility
18 Years and older
Enrollment
337 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2026
U.S. locations
39
States / cities
Duarte, California • Encinitas, California • Orange, California + 30 more
Source: ClinicalTrials.gov public record
Updated Jul 14, 2026 · Synced Oct 23, 2026, 1:29 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

The Effect of Final Exam Preparation on Anxiety Level, Self-Perception, Ocular Symptoms, Accommodation and Vergence in Myopia

NCT00405106
View directory record Official record
Conditions
Myopia
Interventions
Not listed
Lead sponsor
Southern California College of Optometry at Marshall B. Ketchum University
Other
Eligibility
20 Years to 35 Years
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2006
U.S. locations
1
States / cities
Fullerton, California
Source: ClinicalTrials.gov public record
Updated Nov 29, 2006 · Synced Oct 23, 2026, 1:29 AM EDT
Completed Phase 2 Interventional

Topical Ocular Mecamylamine in Diabetic Macular Edema (DME)

NCT00536692
View directory record Official record
Conditions
Diabetic Macular Edema
Interventions
mecamylamine
Drug
Lead sponsor
CoMentis
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
3
States / cities
Oakland, California • Baltimore, Maryland • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 8, 2008 · Synced Oct 23, 2026, 1:29 AM EDT
Completed Not applicable Interventional

Dichoptic Video Treatment for Amblyopia

NCT03825107
View directory record Official record
Conditions
Amblyopia
Interventions
patching, Dichoptic videos
Other
Lead sponsor
Retina Foundation of the Southwest
Other
Eligibility
3 Years to 7 Years
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jan 24, 2025 · Synced Oct 23, 2026, 1:29 AM EDT
Completed Not applicable Interventional

Nonvisual Foot Examination for People With Diabetes and Visual Impairment

NCT02102958
View directory record Official record
Conditions
Diabetes, Visual Impairment
Interventions
DSME with Nonvisual Foot Examination, DSME with Usual Foot Examination Instruction
Behavioral
Lead sponsor
Case Western Reserve University
Other
Eligibility
18 Years and older
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 14, 2023 · Synced Oct 23, 2026, 1:29 AM EDT
Completed Phase 4 Interventional Results available

Evaluation of 3 Intraocular Lenses Following Lens Extraction

NCT01122576
View directory record Official record
Conditions
Cataract
Interventions
Crystalens AO, ReSTOR, Tecnis Multifocal IOL
Device
Lead sponsor
Bausch & Lomb Incorporated
Industry
Eligibility
40 Years and older
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Aliso Viejo, California
Source: ClinicalTrials.gov public record
Updated Mar 28, 2014 · Synced Oct 23, 2026, 1:29 AM EDT
Suspended No phase listed Observational

A Validation of the Functional Low-Vision Observer Rated Assessment (FLORA-20) for Profoundly Blind Individuals

NCT04312763
View directory record Official record
Conditions
Blindness, Acquired
Interventions
Not listed
Lead sponsor
Second Sight Medical Products
Industry
Eligibility
22 Years to 74 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
1
States / cities
Sylmar, California
Source: ClinicalTrials.gov public record
Updated Nov 22, 2023 · Synced Oct 23, 2026, 1:29 AM EDT
Completed Phase 1 Interventional

ADVM-022 Intravitreal Gene Therapy for Wet AMD

NCT03748784
View directory record Official record
Conditions
Wet Age-related Macular Degeneration, Neovascular Age-related Macular Degeneration
Interventions
ADVM-022
Biological
Lead sponsor
Adverum Biotechnologies, Inc.
Industry
Eligibility
50 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
11
States / cities
Bakersfield, California • Beverly Hills, California • Golden, Colorado + 8 more
Source: ClinicalTrials.gov public record
Updated Aug 8, 2023 · Synced Oct 23, 2026, 1:29 AM EDT
Not listed Phase 4 Interventional

Ocular Allergy Treatment Practical Impact Trial

NCT01808768
View directory record Official record
Conditions
Allergic Conjunctivitis, Rhinoconjunctivitis
Interventions
Alcaftadine
Drug
Lead sponsor
Starx Research Center, LLC
Industry
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
2
States / cities
Edison, New Jersey • Springfield, New Jersey
Source: ClinicalTrials.gov public record
Updated May 30, 2013 · Synced Oct 23, 2026, 1:29 AM EDT
Recruiting Not applicable Interventional

Patch-free Occlusion Therapy

NCT05440448
View directory record Official record
Conditions
Amblyopia
Interventions
Patch-free occlusion therapy, Adhesive patch
Device
Lead sponsor
Retina Foundation of the Southwest
Other
Eligibility
3 Years to 12 Years
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jan 7, 2026 · Synced Oct 23, 2026, 1:29 AM EDT
Not listed Not applicable Interventional

Effects of Xal-Ease on Patient Compliance With Xalatan

NCT00573638
View directory record Official record
Conditions
Glaucoma
Interventions
Xal-Ease device to be used with Xalatan eye drops
Device
Lead sponsor
Augusta University
Other
Eligibility
40 Years to 80 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
1
States / cities
Augusta, Georgia
Source: ClinicalTrials.gov public record
Updated Aug 8, 2008 · Synced Oct 23, 2026, 1:29 AM EDT
Recruiting Phase 3 Interventional

Dichoptic Treatment for Amblyopia in Children 4 to 7 Years of Age

NCT06380517
View directory record Official record
Conditions
Amblyopia
Interventions
Luminopia, Eye Patch
Device · Other
Lead sponsor
Jaeb Center for Health Research
Other
Eligibility
4 Years to 7 Years
Enrollment
238 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
72
States / cities
Birmingham, Alabama • Glendale, Arizona • Scottsdale, Arizona + 58 more
Source: ClinicalTrials.gov public record
Updated Feb 11, 2026 · Synced Oct 23, 2026, 1:29 AM EDT
Not listed Phase 4 Interventional

The Effect of Education on Patient Compliance

NCT00376974
View directory record Official record
Conditions
Glaucoma
Interventions
American Academy of Ophthalmology Glaucoma Educational Tape
Behavioral
Lead sponsor
Michael E. DeBakey VA Medical Center
Federal
Eligibility
40 Years to 90 Years · Male only
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 15, 2006 · Synced Oct 23, 2026, 1:29 AM EDT
Completed Not applicable Interventional

Study to Determine if Taking OTC Non-Steroidal Anti-Inflammatory Affects Eye Pressure in Patients Using Glaucoma Drops

NCT00402493
View directory record Official record
Conditions
Glaucoma, Ocular Hypertension
Interventions
ibuprofen, latanoprost, brimonidine, Ibuprofen, brimonidine, latanoprost, Ibuprofen
Drug
Lead sponsor
Philadelphia Eye Associates
Other
Eligibility
21 Years and older
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
3
States / cities
Willingboro, New Jersey • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 4, 2018 · Synced Oct 23, 2026, 1:29 AM EDT
Completed Phase 3 Interventional

Evaluation of Vitrase as a Spreading Agent

NCT00198484
View directory record Official record
Conditions
Pain
Interventions
Vitrase
Drug
Lead sponsor
Bausch & Lomb Incorporated
Industry
Eligibility
18 Years and older
Enrollment
108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
18
States / cities
Newport Beach, California • Sacramento, California • Littleton, Colorado + 15 more
Source: ClinicalTrials.gov public record
Updated Mar 14, 2013 · Synced Oct 23, 2026, 1:29 AM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

P200TE and Predicate Agreement and Precision Study

NCT05624593
View directory record Official record
Conditions
Normal, Retina Disease, Glaucoma
Interventions
P200TE, Predicate
Device
Lead sponsor
Optos, PLC
Industry
Eligibility
22 Years and older
Enrollment
125 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Nov 22, 2022 · Synced Oct 23, 2026, 1:29 AM EDT
Completed Not applicable Interventional

Water Drinking Test in Patients With Occludable Angle

NCT02613533
View directory record Official record
Conditions
Glaucoma
Interventions
Intra-ocular pressure measurement (IOP)
Other
Lead sponsor
Wills Eye
Other
Eligibility
21 Years to 90 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 30, 2017 · Synced Oct 23, 2026, 1:29 AM EDT
Completed Phase 3 Interventional

GTS400 Stent Implantation in Conjunction With Cataract Surgery in Subjects With Open-angle Glaucoma

NCT01052558
View directory record Official record
Conditions
Glaucoma
Interventions
iStent Inject (GTS400), Cataract Surgery
Device · Procedure
Lead sponsor
Glaukos Corporation
Industry
Eligibility
18 Years to 90 Years
Enrollment
164 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
22
States / cities
Rogers, Arkansas • Petaluma, California • Parker, Colorado + 19 more
Source: ClinicalTrials.gov public record
Updated May 19, 2015 · Synced Oct 23, 2026, 1:29 AM EDT
Terminated Phase 1 Interventional

Exploratory Study to Investigate the Bioactivity, Ocular and Systemic Safety, Tolerability, and Pharmacokinetics Following Single and Multiple Intravitreal Administrations of KSI-301 in Subjects With wAMD, DME and RVO

NCT03790852
View directory record Official record
Conditions
Wet Age-related Macular Degeneration, Retinal Vein Occlusion, Diabetic Macular Edema
Interventions
KSI-301
Drug
Lead sponsor
Kodiak Sciences Inc
Industry
Eligibility
21 Years and older
Enrollment
121 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
11
States / cities
Phoenix, Arizona • Beverly Hills, California • Mountain View, California + 8 more
Source: ClinicalTrials.gov public record
Updated Mar 20, 2024 · Synced Oct 23, 2026, 1:29 AM EDT
Completed Not applicable Interventional

Low Vision Occupational Therapy in Parkinson's Disease

NCT04127838
View directory record Official record
Conditions
Parkinson Disease
Interventions
Low Vision Occupational Therapy
Behavioral
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Jun 7, 2022 · Synced Oct 23, 2026, 1:29 AM EDT
Active, not recruiting No phase listed Observational

Wearable Sensors and Video Recordings to Monitor Motor Development

NCT03770832
View directory record Official record
Conditions
Motor Delay, Neurodevelopmental Disorders, Developmental Disability
Interventions
Not listed
Lead sponsor
Shirley Ryan AbilityLab
Other
Eligibility
0 Months to 24 Months
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
2
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jan 21, 2026 · Synced Oct 23, 2026, 1:29 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

An Active Approach to Treat Amblyopia: Video Game Play

NCT01223716
View directory record Official record
Conditions
Amblyopia
Interventions
Perceptual learning, Video Game, Crossover (Occlusion therapy + Video Game)
Behavioral
Lead sponsor
University of California, Berkeley
Other
Eligibility
5 Years to 75 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2009
U.S. locations
1
States / cities
Berkeley, California
Source: ClinicalTrials.gov public record
Updated May 17, 2016 · Synced Oct 23, 2026, 1:29 AM EDT
Recruiting Phase 3 Interventional

Long-term Safety Study of Rimegepant in Pediatric Subjects for the Acute Treatment of Migraine

NCT04743141
View directory record Official record
Conditions
Acute Treatment of Migraine
Interventions
Rimegepant (PF-07899801)
Drug
Lead sponsor
Pfizer
Industry
Eligibility
6 Years to 17 Years
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2030
U.S. locations
115
States / cities
Scottsdale, Arizona • Tempe, Arizona • Anaheim, California + 77 more
Source: ClinicalTrials.gov public record
Updated Sep 24, 2026 · Synced Oct 23, 2026, 1:29 AM EDT